The Council for Responsible Nutrition (CRN) and the Natural Products Association (NPA) have submitted responses to a Congressional Request for Information (RFI) seeking insight from industry stakeholders on CBD in order to develop “a regulatory pathway for non-intoxicating hemp-derived cannabinoid products that prioritizes consumer safety and provides certainty to the U.S. markets.”
According to CRN, FDA (U.S. Food and Drug Administration) has spent the past five years ignoring not only Congress’ directive to regulate CBD, but also the credible, well-conducted research that demonstrates the safety of well-made CBD products. FDA’s failure to establish a regulatory pathway for CBD has forced states to enact their own disparate policies to protect consumers. This has resulted in a patchwork of laws that is detrimental to the industry and should be unified by federal intervention, the Association stated.
“Congress is asking the right questions, because they created in DSHEA (Dietary Supplement Health and Education Act of 1994) a framework that could accommodate CBD, and their reasonable expectations for the FDA around this ingredient were not met,” said CRN President and CEO Steve Mister. “Meanwhile, despite an overwhelming amount of safety data the industry has already presented to FDA, the agency continues to place an entire industry in innovation-stifling limbo, and consumers at continued risk in a needlessly unsupervised…
MMP News Author
Source link
